Point Biopharma’s radiopharmaceutical prostate cancer therapy, PNT2002, reached its main goal in a clinical trial, yet questions were raised about its effectiveness against a similar Novartis drug. The Point therapy showed a 29% reduction in the risk of radiographic progression or death compared to control drugs, but was less effective than expected, potentially impacting the commercial viability of PNT2002. Point and partner Lantheus plan to report further data next year.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
